Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01760759 · ClinicalTrials.gov registry record · NA
Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus
A NA study, sponsored by UConn Health.
- Completed
- Registry status
- NA
- Development phase
- 104
- Enrollment target
NCT01760759: Completed NA study, sponsored by UConn Health.
NCT01760759 is a NA study that has completed, run by UConn Health. The registered enrollment target is 104 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01760759, a NA study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 104 participants
- Enrollment target
Study Summary
In this study, investigators propose to randomize 165 human immunodeficiency virus positive patients to one of three 16-week treatment conditions: (1) standard care; (2) standard care + cell phone-based adherence reminders; or (3) standard care + cell phone-based adherence reminders and contingency management. In this latter condition, patients will earn reinforcement for sending in time- and date-stamped self videos of antiretroviral therapy medication ingestion. Primary outcomes will include viral loads and self-report measures of adherence, and effects will be evaluated both during the treatment period and throughout a one-year follow-up. Investigators hypothesize that the cell phone reminder condition will improve adherence relative to standard care, and the cell phone reminder plus contingency management condition will have the best outcomes. Results from this study may have widespread implications for the use of cell phones as a novel technology to improve initial adherence to antiretroviral therapy, thereby reducing the spread of drug resistant human immunodeficiency virus strains to the community.
Interventions
- BEHAVIORAL cell phone reminders
- BEHAVIORAL contingency management for adherence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2012-11 |
| Est. Completion | 2019-04 |
| Phase | NA |
What the finished NCT01760759 record still lists
NCT01760759 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which cell phone reminders is the first listed.
NCT01760759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01760759 about?
NCT01760759 is a clinical study titled "Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus". In this study, investigators propose to randomize 165 human immunodeficiency virus positive patients to one of three 16-week treatment conditions: (1) standard care; (2) standard care + cell phone-based adherence reminders; or (3) standard care + cell phone-based adherence reminders and contingency ...
What is the current status of trial NCT01760759?
This trial is currently completed. It is a NA study. The enrollment target is 104 participants. The study started on 2012-11. Estimated completion is 2019-04.
What interventions are being tested in trial NCT01760759?
The interventions under investigation include: cell phone reminders (BEHAVIORAL), contingency management for adherence (BEHAVIORAL).
Who is sponsoring clinical trial NCT01760759?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01760759's enrollment target sits among peer trials
104 836th of 2000 higher than 1,164 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia